Screener
Pfizer PFE Cash Flow Statement
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| -$237M-108% | $2.7B-9.3% | —— | $3.55B-20.6% | $2.93B+6,000% | ||
| —— | $1.61B-0.3% | $1.69B-5.8% | $1.66B-5.3% | $1.63B-6.1% | ||
| —— | $272M+60.0% | $225M+27.1% | $201M-26.6% | $203M-1.5% | ||
| —— | $2.62B+12.0% | $5.35B-20.4% | $4.6B-31.4% | $0+100% | ||
| —— | $436M-22.7% | $845M-7.9% | $602M-7.5% | $618M-3.0% | ||
| —— | $785M-76.0% | -$6.15B— | -$2.43B— | $3.95B-14.1% | ||
| —— | -$2.86B+45.4% | $0+100% | -$2.48B+46.6% | -$3.2B-30.0% | ||
| —— | $563M+50.1% | —— | —— | $213M— |
FAQ
- Where does Pfizer's cash flow data come from?
- Every line is extracted from Pfizer's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
